Financial News
Articles published by AstraZeneca
![](https://mms.businesswire.com/media/20220701005091/en/484259/5/Logo.jpg)
![](https://mms.businesswire.com/media/20220621005200/en/484259/5/Logo.jpg)
![](https://mms.businesswire.com/media/20220621005450/en/484259/5/Logo.jpg)
![](https://mms.businesswire.com/media/20220605005070/en/484259/5/Logo.jpg)
![](https://mms.businesswire.com/media/20220604005021/en/484259/5/Logo.jpg)
![](https://mms.businesswire.com/media/20220527005081/en/484259/5/Logo.jpg)
![](https://mms.businesswire.com/media/20220523005269/en/484259/5/Logo.jpg)
![](https://mms.businesswire.com/media/20220515005046/en/484259/5/Logo.jpg)
![](https://mms.businesswire.com/media/20220505005276/en/484259/5/Logo.jpg)
![](https://mms.businesswire.com/media/20220505005582/en/484259/5/Logo.jpg)
![](https://mms.businesswire.com/media/20220505005260/en/484259/5/Logo.jpg)
![](https://mms.businesswire.com/media/20220504005254/en/484259/5/Logo.jpg)
![](https://mms.businesswire.com/media/20220428005462/en/484259/5/Logo.jpg)
ULTOMIRIS® (ravulizumab-cwvz) Approved in the US for Adults with Generalized Myasthenia Gravis
April 28, 2022
From AstraZeneca
Via Business Wire
Tickers
AZN
![](https://mms.businesswire.com/media/20220427005187/en/484259/5/Logo.jpg)
![](https://mms.businesswire.com/media/20220425005340/en/484259/5/Logo.jpg)
![](https://mms.businesswire.com/media/20220420006206/en/484259/5/Logo.jpg)
![](https://mms.businesswire.com/media/20220419005266/en/484259/5/Logo.jpg)
![](https://mms.businesswire.com/media/20220406005286/en/1412362/5/Chart_4.5.22_US_Version.jpg)
![](https://mms.businesswire.com/media/20220324005259/en/484259/5/Logo.jpg)
AstraZeneca Announces New Partnership with The National Fish and Wildlife Foundation to Plant One Million Trees
March 24, 2022
From AstraZeneca
Via Business Wire
Tickers
AZN
![](https://mms.businesswire.com/media/20220321005347/en/484259/5/Logo.jpg)
![](https://mms.businesswire.com/media/20220316005688/en/484259/5/Logo.jpg)
![](https://mms.businesswire.com/media/20220221005258/en/484259/5/Logo.jpg)
![](https://mms.businesswire.com/media/20220214005718/en/1359067/5/Logo.jpg)
![](https://mms.businesswire.com/media/20220124005039/en/484259/5/Logo.jpg)
Eplontersen granted Orphan Drug Designation in the US for transthyretin amyloidosis
January 24, 2022
From AstraZeneca
Via Business Wire
Tickers
AZN
![](https://mms.businesswire.com/media/20220118006249/en/484259/5/Logo.jpg)
![](https://mms.businesswire.com/media/20220118006248/en/484259/5/Logo.jpg)
IMFINZI® (durvalumab) Plus Chemotherapy Reduced Risk of Death by 20% in 1st-Line Advanced Biliary Tract Cancer
January 18, 2022
From AstraZeneca
Via Business Wire
Tickers
AZN
![](https://mms.businesswire.com/media/20220117005097/en/484259/5/Logo.jpg)
![](https://mms.businesswire.com/media/20220117005097/en/484259/5/Logo.jpg)
![](https://mms.businesswire.com/media/20220113005318/en/484259/5/Logo.jpg)
![](https://mms.businesswire.com/media/20220113005298/en/484259/5/Logo.jpg)
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.